CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening
Medicare coverage will provide approximately 65 million eligible Medicare beneficiaries access to the first FDA-approved colon cancer screening stool-RNA test
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved coverage for FDA-approved ColoSense, a stool-based colorectal (CRC) screening test, within the National Coverage Determination (NCD) for colorectal cancer screening tests.
Coverage for ColoSense provides Medicare's approximately 65 million eligible beneficiaries with access to the first FDA-approved, high-sensitivity stool-RNA test that addresses one of the most commonly cited barriers to stool-based screening: the need to handle the sample during collection.1 ColoSense requires only three simple steps, with no stool scraping required, eliminating the need for patients to manipulate the stool sample, while maintaining clinical performance for detection of colorectal cancer and advanced adenomas.
Forward-Thinking Coverage Framework Supports Innovation
